AscellaHealth

At AscellaHealth, we are incredibly grateful for the opportunity to serve the specialty pharmaceutical industry, delivering innovative solutions that meet the unique needs of our clients, partners and patients with complex, chronic conditions and rare diseases. From all of us here, we wish you a joyous holiday season filled with health and happiness, and a wonderful New Year full of opportunity and success! #SeasonGreetings #HappyHolidays #ThankYou #SpecialtyPharmacy #RareDisease #Pharmaceutical #newyear2025

As we look towards 2025, we’re seeing industry trends such as the accessibility of decentralized clinical trials (DCTs) and the personalization of patient care services taking center stage.    Discover how AscellaHealth is strategically positioned to support pharmaceutical manufacturers in navigating these innovations and driving success through partnership in the new year.    Read more in our latest article: https://lnkd.in/ecWvfwyf   #AscellaHealth #LifeSciences #SpecialtyPharmacy #DCTs #PatientCare #DrugDiscovery #PatientAccess #ClinicalTrials #2025HealthcareTrends 

Healthcare payers carry a dual responsibility: to their clients and the patients they serve. But what does this mean in practice and how are clinical trials involved? In our latest 2-part podcast episode, AscellaHealth’s Donovan Quill, Robert J. Gilkin Jr., RPh, MBA, and Andy Szczotka discuss this critical topic. They explore the intersection of payer strategy and clinical trials and why early collaboration between payers and commercial teams is essential. Listen to the full episode and discover how early discussions can pave the way for better patient outcomes: https://lnkd.in/e6BjnCRP #AscellaHealth #AscellaHealthPodcastPulse #RareDisease #SpecialtyPharmacy #LifeSciences #Payers #ClinicalTrials #Spotify

As we look ahead to 2025, healthcare is evolving towards a more patient-centric, efficient, and accessible future. As prescription drug costs rise, key industry shifts have presented valuable opportunities to explore reimbursement adjustments and enhance benefit management, ensuring better access to high-quality treatments. Learn more in AscellaHealth's latest article, How 2025 Will Transform Pharmacy Benefits for Payers, to discover how these shifts are primed to change the industry in the year ahead. Read more here: https://lnkd.in/eS-uVjGs #HealthcareTrends #Reimbursement #AscellaHealth #RareDisease #SpecialtyPharmacy #LifeSciences 

AscellaHealth Podcast Pulse has just launched a new episode closely examining clinical trials in specialty pharmaceuticals. Join Donovan Quill, EVP of Business Development, Growth & Strategy; Andy Szczotka, AscellaHealth’s Chief Pharmacy Officer and Robert J. Gilkin Jr., RPh, MBA, Senior VP of Trade and Specialty Strategy; as they discuss what payers are really looking for when it comes to clinical trials and the critical collaboration that’s needed early on between payers and commercial teams in designing trials that pave the way for better patient access and treatment success. Listen here: https://lnkd.in/e6BjnCRP #AscellaHealth #AscellaHealthPodcastPulse #RareDisease #SpecialtyPharmacy #LifeSciences #Payers #ClinicalTrials #Spotify

2024 was a year of transformative growth for the specialty pharmaceutical industry. From breakthrough advancements in AI and machine learning to evolving regulatory landscapes in the U.S. and EU, there has been significant change. At the center of it all, there’s been a concerted effort toward personalized patient care, which enhances access and improves outcomes. As we look ahead to 2025, what trends and milestones should we expect next? AscellaHealth's latest article, 2024 Specialty Pharmaceutical Review: Key Highlights and Industry Trends, provides an in-depth recap of this year’s key developments and a forward-focused perspective on the future of the industry. Read more here: https://lnkd.in/ecWvfwyf #PharmaInnovation #HealthcareTrends #AscellaHealth #RareDisease #SpecialtyPharmacy #LifeSciences 

Gillian Molloy, VP of Market Access, EU/UK at AscellaHealth, shared her insights on navigating global market access complexities for rare and complex conditions in pharmaphorum. In part two of the series on shaping a more equitable future for rare disease care, she discusses strategies for optimizing patient access and reimbursement, including cost-effectiveness thresholds and leveraging real-world evidence. Read more: https://lnkd.in/gi4xf8mY #AscellaHealth #RWE #RareDisease #SpecialtyPharmacy #LifeSciences #MarketAccess 

Andy Szczotka, Chief Pharmacy Officer at AscellaHealth, recently shared valuable insights with Radar on Specialty Pharmacy, discussing the potential impact of supply disruptions for compounded Avastin in ophthalmology. He also highlighted the introduction of Pavblu, a biosimilar for Eylea, as a treatment option to support patient access amidst sourcing challenges in practices. A special thank you to MMIT (Managed Markets Insight & Technology) and Angela Maas for featuring us once again! Read more: https://lnkd.in/euHrQweA #SpecialtyPharmacy #Ophthalmology #Biosimilars #HealthcareInnovation #PatientAccess #PharmacyLeadership #DrugShortages #PharmaNews

Gillian Molloy, VP of Market Access, EU/UK, at AscellaHealth, recently authored a two-part series in pharmaphorum discussing the challenges and opportunities in global market access for rare and complex conditions. As drug development accelerates, complexity increases for pharmaceutical manufacturers. In part one, Gillian emphasizes the need for innovation and collaboration to navigate country-specific reimbursement landscapes, align pricing strategies, and ensure transformative therapies reach those in need. Read More: https://lnkd.in/eC4MNMR4 #AscellaHealth #RareDisease #SpecialtyPharmacy #LifeSciences #MarketAccess 

With healthcare costs expected to increase by 7% to 9% next year, payers must identify and adopt innovative strategies that can optimize benefit spend and reduce expenses. These escalating costs leave payers faced with a tricky balancing act of managing the financial impact of specialty drugs while still maintaining a high standard of care for their members.   Click the link below to discover five key strategies designed to help payers tackle rising drug costs and leverage more efficient cost management methods: https://lnkd.in/e5WCBU3A